Leads Biolabs to Present Encouraging Clinical Data on Innovative Bispecific Antibody LBL-034 at the 66th ASH Annual Meeting

The 66th Annual Meeting of the American Society of Hematology (ASH 2024) will take place in San Diego, California, from December 7th to 10th. LBL-034, a humanized bispecific T-cell engager targeting both GPRC5D and CD3 which is independently developed by Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") with global intellectual property rights, will be showcased in a poster presentation (abstract #4736) from 6:00 PM to 8:00 PM on December 9^th (Pacific Time). This will be the second time LBL-034 features on the ASH stage, following the presentation of its preclinical data at ASH 2023.

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said “LBL-034 was selected for this year's ASH Annual Meeting due to its exceptional clinical data, marking the initial academic recognition of its efficacy and clinical potential. However, the surprises brought by LBL-034 go far beyond this. In the latest clinical data readout on November 22nd, LBL-034 showed a trend of further improvement in key efficacy indicators with increasing doses and extending treatment cycles. These excellent clinical data not only further strengthen our confidence in the clinical potential of LBL-034 but also heighten our anticipation of being able to provide a novel and more effective treatment option to patients with RRMM as early as possible.”

Dr. Xiaoqiang Kang, founder, chairman and CEO of Leads Biolabs, said “I am thrilled to see LBL-034 selected once again for the ASH Annual Meeting. Last year, at the ASH Annual Meeting, we unveiled the unique molecular design and the preclinical data for LBL-034. And this year, we further present its impressive clinical data, thanks to the efficient progress and tireless efforts of our team. We will continue to accelerate the development of LBL-034, with the goal of bringing great treatment to RRMM patients as soon as possible.”